Anti-O1 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12018068-B2
Application number	US-202117397474-A
Country	US
Kind code	B2
Filing date	Aug 9, 2021
Priority date	Oct 19, 2016
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

First claim

What is claimed is:

1. A method for treating or ameliorating a Klebsiella infection in a subject in need thereof comprising administering to said subject an effective amount of an antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen comprising a set of Complementarity-Determining Regions (CDRs): HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3
wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of:
SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively;
SEQ ID NOs: 1, 2, 3, 4, 6, and 7, respectively; or
SEQ ID NOs: 1, 2, 3, 4, 5, and 11, respectively.

2. The method of claim 1 , wherein the administration results in inhibiting the growth of Klebsiella or reducing the number of Klebsiella in the subject infected with Klebsiella.

3. A method for protecting against a Klebsiella infection in a subject in need thereof comprising administering to said subject an effective amount of antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen, wherein the antigen binding protein comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively; SEQ ID NOs: 1, 2, 3, 4, 6, and 7, respectively; or SEQ ID NOs: 1, 2, 3, 4, 5, and 11, respectively.

4. A method for treating or ameliorating a Klebsiella pneumoniae and Staphylococcus aureus co-infection in a subject in need thereof comprising administering to said subject an effective amount of an antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen, wherein the antigen binding protein comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively; SEQ ID NOs: 1, 2, 3, 4, 6, and 7, respectively; or SEQ ID NOs: 1, 2, 3, 4, 5, and 11, respectively.

5. The method of claim 1 , wherein the Klebsiella is antibiotic-resistant.

6. The method of claim 5 , wherein the Klebsiella is resistant to cephalosporin, quinolone, carbapenam, meropenem, fluoroquinolone, tetracycline, chloramphenicol, trimethoprim, sulfonamide, and/or colistin.

7. The method of claim 1 , wherein the Klebsiella is susceptible to antibiotics.

8. The method of claim 1 , further comprising administering an antibiotic.

9. The method of claim 8 , wherein the antigen binding protein and the antibiotic provide a synergistic therapeutic effect.

10. The method of claim 8 , wherein the administration of the antigen binding protein and the antibiotic provides a therapeutic effect greater than the sum of the individual effects of administration of equal molar quantities of the antigen binding protein or the antibiotic.

11. The method of claim 10 , wherein the therapeutic effect results in greater percent survival than the additive percent survival of subjects to which only one of the antigen binding protein or the antibiotic was administered.

12. The method of claim 11 , wherein the antibiotic is meropenem.

13. The method of claim 1 , wherein the antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen is an antibody or antigen binding fragment thereof.

14. The method of claim 1 , wherein the Klebsiella is K. pneumoniae, K. oxytoca, K. planticola, K. ozaenae, K. rhinoscleromatis and/or K. granulomatis.

15. The method of claim 1 , wherein the infection is selected from the group consisting of pneumonia, urinary tract infection, septicemia/sepsis, neonatal septicemia/sepsis, diarrhea, soft tissue infection, infection following an organ transplant, surgery infection, wound infection, lung infection, pyogenic liver abscesses (PLA), endophthalmitis, meningitis, necrotizing meningitis, ankylosing spondylitis, and spondyloarthropathies.

16. The method of claim 1 , wherein the infection is a nosocomial infection.

17. The method of claim 13 , wherein the antigen binding protein comprises a VH comprising SEQ ID NO:8 and a VL comprising SEQ ID NO:9.

18. The method of claim 17 , wherein the antigen binding protein comprises a human IgG1 constant domain and a human lambda constant domain.

19. The method of claim 1 , wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively.

20. The method of claim 1 , wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 6, and 7, respectively.

21. The method of claim 3 , wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively.

22. The method of claim 3 , wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 6, and 7, respectively.

23. The method of claim 3 , wherein the antigen binding protein comprises a VH comprising SEQ ID NO:8 and a VL comprising SEQ ID NO:9.

Assignees

• Medimmune Llc
• Humabs Biomed Sa

Inventors

• Wang Qun
• Stover Charles K
• Pennini Meghan
• Chang Chew-Shun
• Xiao Xiaodong
• Hilliard Jamese
• Kaplan Gilad
• Corti Davide
• Cameroni Elisabetta
• Beltramello Martina

Classifications

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/31

  multispecific · CPC title